These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17325287)

  • 1. Neuroprotective agents for clinical trials in ALS: systematic assessment.
    Burke WJ
    Neurology; 2007 Feb; 68(9):709; author reply 710. PubMed ID: 17325287
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
    Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
    Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic trials in ALS.
    Bradley W
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
    [No Abstract]   [Full Text] [Related]  

  • 4. Designing clinical trials in amyotrophic lateral sclerosis.
    Shefner JM
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. We have a problem: why have ALS trials been negative?
    Swash M
    Amyotroph Lateral Scler; 2007 Oct; 8(5):259. PubMed ID: 17917847
    [No Abstract]   [Full Text] [Related]  

  • 7. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial.
    Levin BJ; Thompson G; Mitsumoto LH; Kaufmann P
    Neurology; 2006 Jun; 66(11):1786-7; author reply 1786-7. PubMed ID: 16769973
    [No Abstract]   [Full Text] [Related]  

  • 8. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F; Tashiro K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
    Davies SL; Moral MA
    Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting promising ALS therapies in clinical trials.
    Glass JD; Benatar M; Polak M
    Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
    [No Abstract]   [Full Text] [Related]  

  • 11. Commentary on 'a novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS'.
    Shefner JM; Nigel Leigh P
    Amyotroph Lateral Scler; 2008 Aug; 9(4):254-6. PubMed ID: 18642137
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome measures for early phase clinical trials.
    Gordon PH; Cheng B; Montes J; Doorish C; Albert SM; Mitsumoto H
    Amyotroph Lateral Scler; 2007 Oct; 8(5):270-3. PubMed ID: 17852017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and experimental neuroprotection in neurodegenerative diseases is a therapeutic option for the future of amyotrophic lateral sclerosis (ALS). Preface.
    Ludolph AC; Drory VE
    J Neurol; 2000 Dec; 247 Suppl 6():VI/1. PubMed ID: 19714407
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug therapy in amyotrophic lateral sclerosis.
    Distad BJ; Meekins GD; Liou LL; Weiss MD; Carter GT; Miller RG
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):633-51, xi-xii. PubMed ID: 18625421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measures of quality of life: con.
    Borasio GD
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S21-3. PubMed ID: 12396797
    [No Abstract]   [Full Text] [Related]  

  • 16. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What are the etiological medical therapies in amyotrophic lateral sclerosis?].
    Dib M
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S215-4S219. PubMed ID: 17128114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measures of quality of life: pro.
    Ludolph AC
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002; 3 Suppl 1():S19. PubMed ID: 12396796
    [No Abstract]   [Full Text] [Related]  

  • 19. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
    Gámez J
    Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining survival as an outcome measure in amyotrophic lateral sclerosis.
    Gordon PH; Corcia P; Lacomblez L; Pochigaeva K; Abitbol JL; Cudkowicz M; Leigh PN; Meininger V
    Arch Neurol; 2009 Jun; 66(6):758-61. PubMed ID: 19506136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.